|
🐜
|
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
13 auth.
M. Harbord,
R. Eliakim,
D. Bettenworth,
K. Karmiris,
K. Katsanos,
U. Kopylov,
T. Kucharzik,
T. Molnár,
T. Raine,
S. Sebastian,
...
Helena Tavares de Sousa,
A. Dignass,
F. Carbonnel
|
10 |
2017 |
10
🐜
|
|
🐜
|
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
24 auth.
K. Gecse,
B. Lovász,
K. Farkas,
J. Banai,
L. Bene,
B. Gasztonyi,
P. Golovics,
T. Kristof,
L. Lakatos,
Á. Csontos,
...
M. Juhász,
F. Nagy,
K. Palatka,
M. Papp,
Á. Patai,
L. Lakner,
Á. Salamon,
T. Szamosi,
Z. Szepes,
G. Tóth,
Á. Vincze,
B. Szalay,
T. Molnár,
P. Lakatos
|
7 |
2016 |
7
🐜
|
|
🐜
|
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease
24 auth.
L. Kiss,
T. Szamosi,
T. Molnár,
P. Miheller,
L. Lakatos,
Á. Vincze,
K. Palatka,
Z. Barta,
B. Gasztonyi,
Á. Salamon,
...
Gábor Horváth,
G. Tóth,
K. Farkas,
J. Banai,
Z. Tulassay,
F. Nagy,
Mária Szenes,
G. Veres,
B. Lovász,
Z. Végh,
P. Golovics,
M. Szathmári,
M. Papp,
P. Lakatos
|
7 |
2011 |
7
🐜
|
|
🐜
|
New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort
18 auth.
M. Papp,
I. Altorjay,
N. Dotan,
K. Palatka,
I. Foldi,
J. Tumpek,
S. Sipka,
M. Udvardy,
T. Dinya,
L. Lakatos,
...
Á. Kovács,
T. Molnár,
Z. Tulassay,
P. Miheller,
G. Norman,
T. Szamosi,
J. Papp,
P. Lakatos
|
7 |
2008 |
7
🐜
|
|
🐜
|
IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease
10 auth.
A. Nemetz,
M. P. Nosti-Escanilla,
T. Molnár,
A. Köpe,
Á. Kovács,
J. Féher,
...
Z. Tulassay,
F. Nagy,
M. García-González,
A. Peña
|
7 |
1999 |
7
🐜
|
|
🐜
|
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations.
11 auth.
P. Lakatos,
L. Lakatos,
F. Szalay,
C. Willheim-Polli,
C. Osterreicher,
Z. Tulassay,
...
T. Molnár,
W. Reinisch,
J. Papp,
G. Mózsik,
P. Ferenci
|
7 |
2005 |
7
🐜
|
|
🐜
|
A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome.
11 auth.
R. Róka,
A. Rosztóczy,
M. Lévêque,
F. Izbéki,
F. Nagy,
T. Molnár,
...
J. Lonovics,
R. Garcia-Villar,
J. Fioramonti,
T. Wittmann,
L. Buéno
|
7 |
2007 |
7
🐜
|
|
🐜
|
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.
27 auth.
H. Gordon,
L. Biancone,
G. Fiorino,
K. Katsanos,
U. Kopylov,
Eman Al Sulais,
J. Axelrad,
Karthiha Balendran,
J. Burisch,
L. de Ridder,
L. Derikx,
P. Ellul,
T. Greuter,
M. Iacucci,
Caroline di Jiang,
...
C. Kapizioni,
K. Karmiris,
J. Kirchgesner,
D. Laharie,
Triana Lobatón Ortega,
T. Molnár,
N. Noor,
R. Rao,
S. Saibeni,
M. Scharl,
S. Vavricka,
T. Raine
|
6 |
2022 |
6
🐜
|
|
🐜
|
Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice
11 auth.
A. Annaházi,
K. Gecse,
M. Dabek,
A. Ait-Belgnaoui,
A. Rosztóczy,
R. Róka,
...
T. Molnár,
V. Théodorou,
T. Wittmann,
L. Buéno,
H. Eutamene
|
6 |
2009 |
6
🐜
|
|
🐜
|
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients
21 auth.
M. Papp,
I. Altorjay,
G. Norman,
Z. Shums,
K. Palatka,
Z. Vitális,
I. Foldi,
G. Lakos,
J. Tumpek,
M. Udvardy,
...
J. Hársfalvi,
S. Fischer,
L. Lakatos,
Á. Kovács,
L. Bene,
T. Molnár,
Z. Tulassay,
P. Miheller,
G. Veres,
J. Papp,
P. Lakatos
|
6 |
2007 |
6
🐜
|
|
🐢
|
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center
8 auth.
K. Farkas,
M. Rutka,
A. Bálint,
F. Nagy,
R. Bor,
Á. Milassin,
...
Z. Szepes,
T. Molnár
|
6 |
2015 |
6
🐢
|
